An updated World Health Organization (WHO) classification of female genital tumours was
published in autumn 2020. We discuss the major new additions to and changes from the …

Following the discovery of the four molecular subtypes of endometrial cancer (EC) by The
Cancer Genome Atlas (TCGA) in 2013, subsequent studies used surrogate markers to …

Endometrial carcinoma (EC) can be divided into 4 prognostic molecular subtypes, and no
specific molecular profile (NSMP) type is the most commonly occurring type (∼ 50%) …

Molecular classification provides an objective, reproducible framework for categorization of
endometrial cancers (ECs), informing prognosis and selection of therapy. Currently, the …

Endometrial carcinoma (EC) is traditionally treated with surgery and adjuvant treatment
depending on clinicopathological risk factors. The genomic analysis of EC in 2013 and …

Purpose: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage
I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review …

The human endometrium is a unique tissue undergoing important changes through the
menstrual cycle. Under the exposure of different risk factors in a woman's lifetime, normal …

Background When determining adjuvant treatment for endometrial cancer, the decision
typically relies on factors such as cancer stage, histologic grade, subtype, and a few …

Background The role of lymph node assessment/dissection (LND) in endometrial cancer
(EC) has been debated for decades, with significant practice variation between centers …

Objective To compare the risk class attribution with molecular classification unknown to
those with molecular classification known, according to the European Society of …